Citation Report
List of articles citing

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies

DOI: 10.1016/s0002-9149(03)00075-4
American Journal of Cardiology, 2003, 92, 47M-57M.

Source: https://exaly.com/paper-pdf/35020279/citation-report.pdf
Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
87	Erectile dysfunction in the cardiac patient. *Current Urology Reports*, **2003**, 4, 466-71	2.9	16
86	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. *American Journal of Cardiology*, **2003**, 92, 9M-18M	3	160
85	Roundtable discussion: tadalafil study group. *American Journal of Cardiology*, **2003**, 92, 58M-65M	3	2
84	Emerging oral drugs for erectile dysfunction. *Expert Opinion on Emerging Drugs*, **2004**, 9, 179-189	3.7	4
83	Tadalafil: A Comprehensive Update. **2004**, 2, 225-246		
82	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. *Journal of Pharmacy Practice*, **2004**, 17, 239-250	1.3	1
81	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. *Clinical Cardiology*, **2004**, 27, I14-19	3.3	49
80	Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. *Clinical Cardiology*, **2004**, 27, I20-5	3.3	22
79	Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. *Journal of Urology*, **2004**, 172, 1935-40	2.5	133
78	New treatment options for erectile dysfunction in patients with diabetes mellitus. *Drugs*, **2004**, 64, 2667-88	1.81	69
77	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. *Circulation*, **2004**, 110, 3149-55	16.7	143
76	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. *Therapy: Open Access in Clinical Medicine*, **2004**, 1, 185-196		
75	Phosphodiesterase type 5 inhibitors for erectile dysfunction. *BJU International*, **2005**, 96, 257-80	5.6	153
74	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. *BJU International*, **2005**, 96, 1323-32	5.6	78
73	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. *British Journal of Clinical Pharmacology*, **2005**, 60, 459-68	3.8	19
72	A case of erectile dysfunction and risk factors for coronary artery disease. *International Journal of Impotence Research*, **2005**, 17 Suppl 1, S7-S11	2.3	3
71	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *American Journal of Cardiology*, **2005**, 96, 313-21	3	216

70	Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. *American Journal of Cardiology*, **2005**, 96, 37M-41M	3	36
69	Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. *American Journal of Cardiology*, **2005**, 96, 42M-46M	3	63
68	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *American Journal of Cardiology*, **2005**, 96, 85M-93M	3	99
67	The therapeutic dilemma: how to use tadalafil. *Journal of Developmental and Physical Disabilities*, **2005**, 28 Suppl 2, 74-80		36
66	Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. *Journal of Sexual Medicine*, **2005**, 2, 856-64	1.1	67
65	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. *World Journal of Urology*, **2005**, 23, 374-84	4	25
64	Tadalafil: a clinical update. *Aging Health*, **2005**, 1, 203-214		3
63	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. *Nature Reviews Urology*, **2005**, 2, 239-47		40
62	Disfunci□ sexual en la hipertensi□ arterial. *Hipertension*, **2005**, 22, 59-72		4
61	Hipertensi□ arterial, medicaci□ antihipertensiva y disfunci□ er□til: una perspectiva basada en la evidencia. *Revista Internacional De Andrologí□*, **2005**, 3, 13-30	0.6	5
60	Disfunci□ sexual en la hipertensi□ arterial. *Hipertension Y Riesgo Vascular*, **2005**, 22, 59-72	0.5	0
59	Phosphodiesterase 5 inhibitors for erectile dysfunction. *Annals of Pharmacotherapy*, **2005**, 39, 1286-95	2.9	61
58	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. *Drugs*, **2005**, 65, 1621-50	12.1	133
57	Frequently asked questions about tadalafil for treating men with erectile dysfunction. *The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender*, **2005**, 2, 141-157		1
56	Arterial elasticity and erectile dysfunction in hypertensive men. *Journal of Clinical Hypertension*, **2006**, 8, 768-74	2.3	10
55	Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. *British Journal of Clinical Pharmacology*, **2006**, 62, 280-7	3.8	16
54	Adverse effects of drug therapies on male and female sexual function. *World Journal of Urology*, **2006**, 24, 623-9	4	17
53	Phosphodiesterase-5 inhibitors and their hemodynamic effects. *Current Hypertension Reports*, **2006**, 8, 345-51	4.7	23

52	The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. *Journal of Sexual Medicine*, **2006**, 3, 28-36; discussion 36	1.1	230
51	Hypertension, antihypertensive therapy, and erectile dysfunction. *Angiology*, **2006**, 57, 47-52	2.1	34
50	Erectile dysfunction and hypertension. *International Journal of Impotence Research*, **2007**, 19, 296-302	2.3	67
49	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. *American Journal of the Medical Sciences*, **2007**, 334, 466-80	2.2	14
48	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. *Cardiology in Review*, **2007**, 15, 76-86	3.2	52
47	The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. *International Journal of Impotence Research*, **2007**, 19, 55-61	2.3	57
46	Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. *The Cochrane Library*, **2007**, CD002187	5.2	50
45	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. *International Journal of Impotence Research*, **2007**, 19, 281-95	2.3	33
44	Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. *Journal of Sexual Medicine*, **2007**, 4, 1291-303	1.1	33
43	Phosphodiesterase 5 inhibition in essential hypertension. *Current Hypertension Reports*, **2008**, 10, 52-7	4.7	27
42	Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. *Asian Journal of Andrology*, **2008**, 10, 115-33	2.8	59
41	Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. *Journal of Sexual Medicine*, **2008**, 5, 1066-1078	1.1	38
40	The use of phosphodiesterase 5 inhibitors with concomitant medications. *Journal of Endocrinological Investigation*, **2008**, 31, 799-808	5.2	49
39	The cardiovascular safety of tadalafil. *Expert Opinion on Drug Safety*, **2008**, 7, 43-52	4.1	8
38	Sexual dysfunction: the Ţprima ballerinaTof hypertension-related quality-of-life complications. *Journal of Hypertension*, **2008**, 26, 2074-84	1.9	91
37	Tadalafil in the treatment of erectile dysfunction. *Therapeutics and Clinical Risk Management*, **2008**, 4, 1315-30	2.9	57
36	The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. *Journal of Sexual Medicine*, **2009**, 6, 3166-76	1.1	19
35	Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. *Asian Journal of Andrology*, **2009**, 11, 629-37	2.8	1

34	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. *American Journal of Lifestyle Medicine*, **2009**, 3, 201-211	1.9	1
33	Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions. *Mayo Clinic Proceedings*, **2009**, 84, 139-148	6.4	76
32	Efficacy and safety of mirodenafil in men taking antihypertensive medications. *Journal of Sexual Medicine*, **2010**, 7, 3143-52	1.1	16
31	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*, **2010**, 122, 88-95	16.7	78
30	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. *Clinical Therapeutics*, **2011**, 33, 1590-608	3.5	10
29	Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*, **2012**, 125, 1058-72	16.7	202
28	The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. *Journal of Clinical Hypertension*, **2012**, 14, 644-9	2.3	22
27	Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. *Current Heart Failure Reports*, **2013**, 10, 26-35	2.8	14
26	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. *Current Hypertension Reports*, **2013**, 15, 475-83	4.7	42
25	The effect of udenafil on the hemodynamics of healthy male volunteers administered tamsulosin. *Current Medical Research and Opinion*, **2013**, 29, 685-93	2.5	3
24	Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. *World Journal of Men?s Health*, **2014**, 32, 18-27	6.8	9
23	Sexual activity and ischemic heart disease. *Current Cardiology Reports*, **2014**, 16, 445	4.2	15
22	Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit. *Archives of Medical Science*, **2015**, 11, 190-8	2.9	12
21	New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?. *Current Hypertension Reports*, **2015**, 17, 557	4.7	22
20	Phosphodiesterase type 5 inhibitors and kidney disease. *International Urology and Nephrology*, **2015** , 47, 1521-8	2.3	25
19	Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats. *European Journal of Pharmacology*, **2015**, 765, 574-81	5.3	10
18	Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. *Translational and Clinical Pharmacology*, **2016**, 24, 90	2	
17	Medical treatment of erectile dysfunction: too many medical prescriptions?. *Urologia*, **2017**, 84, 121-129	1.2	3

16	The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. *Translational Andrology and Urology*, **2017**, 6, 295-304	2.3	17
15	Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction. *Revista Da Associação Médica Brasileira*, **2019**, 65, 388-393	1.4	4
14	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. *British Journal of Pharmacology*, **2020**, 177, 5467-5488	8.6	34
13	Possible protective effect of TNF-α inhibition and triad NO/cGMP/VEGF activation on gastric ulcer in rats. *Canadian Journal of Physiology and Pharmacology*, **2021**, 99, 864-874	2.4	1
12	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. **2004**, 139-161		1
11	Tadalafil-loaded PLGA microspheres for pulmonary administration: preparation and evaluation. *Brazilian Journal of Pharmaceutical Sciences*, 55,	1.8	3
10	Sexual function in hypertensive patients receiving treatment. *Vascular Health and Risk Management* , **2006**, 2, 447-55	4.4	31
9	Etiologies and Mechanisms of Ischemic Stroke Associated with Sexual Intercourse: A Literature Review. *Cerebrovascular Diseases*, **2021**, 1-9	3.2	
8	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. **2004**, 159-181		
7	PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension. **2015**, 185-193		
6	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. *Therapy: Open Access in Clinical Medicine*, **2004**, 1, 185-196		
5	Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. *Mayo Clinic Proceedings*, **2009**, 84, 139-48	6.4	29
4	Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications.. *Journal of Clinical Hypertension*, **2022**,	2.3	3
3	Pharmacokinetic Drug Interaction Between Amlodipine and Tadalafil: An Open-Label, Randomized, Multiple-Dose Crossover Study in Healthy Male Volunteers.. *Drug Design, Development and Therapy*, **2022**, 16, 425-433	4.4	1
2	Drug-Drug Interactions in the Management of Patients with Pulmonary Arterial Hypertension. *Chest*, **2022**,	5.3	0
1	Development of a Rapid LC-MS/MS Method for Simultaneous Quantification of Donepezil and Tadalafil in Rat Plasma: Its Application in a Pharmacokinetic Interaction Study after Oral Administration in Rats. **2023**, 28, 2352		0